SCHEMBL421867

SCHEMBL421867

O=C1NC(=O)C2(CCCCC2)N1c1ccc(I)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.37
FAAH O00519 1/20 0.35
MGLL Q99685 1/20 0.35
QPCT Q16769 1/20 0.35
POLB P06746 1/20 0.34
ALDH1A1 P00352 5/20 0.33
MAPK1 P28482 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
TSHR P16473 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MCHR1 Q99705 2/20 0.33
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
SLC6A9 P48067 1/20 0.33
ABL1 P00519 1/20 0.33
SRC P12931 1/20 0.33
MMP13 P45452 1/20 0.32
MAPT P10636 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201840 0.83 POLB (0.51) AKR1B1POLBALDH1A1MAPK1SMN1; SMN2
SCHEMBL17077228 0.83 MAPT (0.45) AKR1B1ALDH1A1OPRM1OPRL1SLC6A9
SCHEMBL18961831 0.83 LMNA (0.46) SMN1; SMN2HSD17B10MCHR1OPRM1OPRL1
SCHEMBL2544529 0.81 MMP13 (0.46) QPCTSMN1; SMN2HSD17B10MCHR1OPRM1
SCHEMBL190640 0.80 ALDH1A1 (0.55) MGLLPOLBALDH1A1MAPK1KDM4E
SCHEMBL18961813 0.78 MAPT (0.47) AKR1B1POLBALDH1A1MAPTLMNA
SCHEMBL25249651 0.77 MMP13 (0.46) QPCTHSD17B10MCHR1OPRM1OPRL1
SCHEMBL660324 0.74 ELANE (0.41) AKR1B1QPCTPOLBALDH1A1SMN1; SMN2
SCHEMBL242118 0.73 SLC6A3 (0.40) AKR1B1QPCTMMP13
SCHEMBL422506 0.72 HTT (0.49) ALDH1A1MAPK1HPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420682-B2 N-phenylacetamide derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-04-16 US disclosed
US-20120021017-A1 N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120021017-A1 N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM SOAT1, SOAT2, NAT1 AKR1B1 1075/4885FAAH 583/4885MGLL 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.